Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1

Target enrollment increased to 155 subjects with the addition of a cohort testing a second dose of LSTA1 Results to be used to explore possible conditional approvals globally Futility analysis... | May 24, 2023

Related Keywords

New Zealand ,The University Of Sydney ,New South Wales ,Australia ,Sydney ,John Menditto ,Exchange Commission ,Corporate Communications ,Clinical Trial Centre ,Nasdaq ,Lisata Therapeutics Inc ,Intestinal Trials Group ,National Health ,Research Council ,Clinical Trials Centre ,University Of Sydney ,Australasian Gastro Intestinal Trials Group ,Medical Research Council ,Executive Vice President ,Chief Medical Officer ,Cendr Platform ,Trials Centre ,Private Securities Litigation Reform Act ,Nasdaq Capital Market ,Annual Report ,Investor Relations ,Lisata Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Target ,Enrollment ,Ncreased ,O ,55 ,Subjects ,Ith ,The ,Addition ,F ,Second ,Nose ,Lsta1 ,Results ,He ,Ased ,Xplore ,Ossible ,Onditional ,Approvals ,Lobally ,Utility Lsta Us1280583022 ,